The Special Interest Groups on New Medicines has formed by the integration of the former SIGs (Drug Design and Discovery, Natural Products, Biotech), adding the element of pharmacology and cell and gene therapy. Our SIG will provide a platform for the discussion of a wide range of research topics in the pharmaceutical sciences related to drug discovery and development. Importantly, this includes early stage drug development, with research areas in medicinal chemistry, natural medicines, pharmacology, cell and gene therapies and biologics. Synergy of these topics will corroborate the important role of pharmacists in health care, with new insights in emerging trends in drug discovery and development.

Takuya Kumamoto (Chair)
TBA (Vice chairs)
Michiho Ito (FG Chair Natural products and Traditional medicines)
Chun-Wai Mai (FG Chair Pharmacology)
Juliet (FG Chair Biologics)
TBA (FG Chairs Small molecules; Cell and gene therapy)
Mathew Cherian (IPS liaison).

Former SIG Drug Design and Discovery, collaborated with CPS, HPS, and IPS, organized session on C1 “Antibiotics and environment” at the Abu Dhabi Annual Meeting.

Goals for 2020:

- Goal #1: Providing the session for World Congress at Brisbane meeting 2021.
- Goal #2: Co-chairing the session at PSWC 2020: D5 - Novel strategies to enhance antimicrobial stewardship: A focus on low- and middle-income countries